These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20306555)

  • 1. Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy.
    Marinda ET; Hargrove J; Preiser W; Slabbert H; van Zyl G; Levin J; Moulton LH; Welte A; Humphrey J
    J Acquir Immune Defic Syndr; 2010 Apr; 53(4):496-9. PubMed ID: 20306555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries.
    Laeyendecker O; Brookmeyer R; Mullis CE; Donnell D; Lingappa J; Celum C; Baeten JM; Campbell MS; Essex M; de Bruyn G; Farquhar C; Quinn TC; Eshleman SH;
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1177-83. PubMed ID: 22283149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CD4+ T cell count and antiretroviral treatment on two serological HIV incidence assays.
    Hladik W; Olara D; Mermin J; Moore D; Were W; Alexander L; Downing R
    AIDS Res Hum Retroviruses; 2012 Jan; 28(1):95-9. PubMed ID: 21314476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased specificity of an assay for recent infection in HIV-1-infected patients on highly active antiretroviral treatment: implications for incidence estimates.
    Chaillon A; Le Vu S; Brunet S; Gras G; Bastides F; Bernard L; Meyer L; Barin F
    Clin Vaccine Immunol; 2012 Aug; 19(8):1248-53. PubMed ID: 22718132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay.
    Laeyendecker O; Brookmeyer R; Oliver AE; Mullis CE; Eaton KP; Mueller AC; Jacobson LP; Margolick JB; Brown J; Rinaldo CR; Quinn TC; Eshleman SH;
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):816-22. PubMed ID: 22014036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of antiretroviral therapy initiation after diagnosis of recent human immunodeficiency virus infection and CD4(+) T-cell recovery.
    Ding Y; Duan S; Wu Z; Ye R; Yang Y; Yao S; Wang J; Xiang L; Jiang Y; Lu L; Jia M; Detels R; He N
    Clin Microbiol Infect; 2016 Mar; 22(3):290.e5-8. PubMed ID: 26627338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of misdiagnosed HIV clients in an Early Access to ART for All implementation study in Swaziland.
    Khan S; Mafara E; Pasipamire M; Spiegelman D; Mazibuko S; Ntshalintshali N; Hettema A; Lejeune C; Walsh F; Okello V
    J Int AIDS Soc; 2017 Aug; 20(Suppl 6):21756. PubMed ID: 28872273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
    Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
    JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
    Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA
    AIDS Res Hum Retroviruses; 2009 Jun; 25(6):756-76. PubMed ID: 19500017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.
    Wendel SK; Mullis CE; Eshleman SH; Blankson JN; Moore RD; Keruly JC; Brookmeyer R; Quinn TC; Laeyendecker O
    PLoS One; 2013; 8(2):e55525. PubMed ID: 23437058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating False-Recent Classification for the Limiting-Antigen Avidity EIA and BED-Capture Enzyme Immunoassay in Vietnam: Implications for HIV-1 Incidence Estimates.
    Shah NS; Duong YT; Le LV; Tuan NA; Parekh BS; Ha HTT; Pham QD; Cuc CTT; Dobbs T; Tram TH; Lien TTX; Wagar N; Yang C; Martin A; Wolfe M; Hien NT; Kim AA
    AIDS Res Hum Retroviruses; 2017 Jun; 33(6):546-554. PubMed ID: 28193090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay.
    Hayashida T; Gatanaga H; Tanuma J; Oka S
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):495-8. PubMed ID: 18327979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short Communication: Assessing Estimates of HIV Incidence with a Recent Infection Testing Algorithm That Includes Viral Load Testing and Exposure to Antiretroviral Therapy.
    Kim AA; Rehle T
    AIDS Res Hum Retroviruses; 2018 Oct; 34(10):863-866. PubMed ID: 29926735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.
    Andrabi R; Makhdoomi MA; Kumar R; Bala M; Parray H; Gupta A; Kotnala A; Thirumurthy V; Luthra K
    J Clin Immunol; 2014 May; 34(4):504-13. PubMed ID: 24682667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community viral load and CD4 count distribution among people living with HIV in a South African Township: implications for treatment as prevention.
    Kranzer K; Lawn SD; Johnson LF; Bekker LG; Wood R
    J Acquir Immune Defic Syndr; 2013 Aug; 63(4):498-505. PubMed ID: 23572010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.